{"data":[{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Bihua Chen","reportingCik":"0001599214","personType":"IN,HC","sharesOwned":17878594,"percentOfClass":22.32,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Cormorant Global Healthcare Master Fund, LP","reportingCik":null,"personType":"PN","sharesOwned":6083221,"percentOfClass":7.59,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Cormorant Global Healthcare GP, LLC","reportingCik":null,"personType":"PN","sharesOwned":6083221,"percentOfClass":7.59,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Cormorant Private Healthcare GP V, LLC","reportingCik":null,"personType":"PN","sharesOwned":5010332,"percentOfClass":6.25,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Cormorant Private Healthcare Fund V, LP","reportingCik":null,"personType":"PN","sharesOwned":5010332,"percentOfClass":6.25,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Cormorant Private Healthcare GP III, LLC","reportingCik":null,"personType":"PN","sharesOwned":4879995,"percentOfClass":6.09,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Cormorant Private Healthcare Fund III, LP","reportingCik":null,"personType":"PN","sharesOwned":4879995,"percentOfClass":6.09,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001213900-26-075546","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":"107924102","securityClass":"Common Stock","eventDate":"2026-07-01","reportingPerson":"Helix Holdings II LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-07-06","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":2528762,"percentOfClass":3.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":2528762,"percentOfClass":3.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":2528762,"percentOfClass":3.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":2538142,"percentOfClass":3.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":9380,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":9380,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0001104659-25-112512","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Class A ordinary share, par value $0.0001 per share (the \"Shares\")","eventDate":"2025-09-30","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":9380,"percentOfClass":0,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0000902664-25-004881","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":1487621,"percentOfClass":1.88,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0000902664-25-004881","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":1487621,"percentOfClass":1.88,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"},{"accessionNo":"0000902664-25-004881","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001869105","issuerName":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":1487621,"percentOfClass":1.88,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/bbot"}],"updatedAt":"2026-11-05T14:37:24.021Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/bbot","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}